Novartis’ strong commitment to the dynamic healthcare sector in the region and elsewhere in the developing world has been recognized in the ‘World’s Most Respected Companies’ list published by the Financial Times, a well-respected British daily.
Novartis was ranked at No. 49 by more than 950 chief executives in 25 countries – an acknowledgement of the standing that the company enjoys in the global business world.
Its activities in the Middle East – which include a Pan Arab program aimed at encouraging a “healthy heart” lifestyle across the region – have provided a key strand of support for this approach.
“Healthcare companies have a significant impact on the lives of people in the societies they operate in. Consequently, and understandably, our activities are open to scrutiny. Our global ranking as one of the world’s most respected companies is an endorsement of our commitment to the core principles of corporate social responsibility,” said Liz MacGillivray, Head of Marketing and Sales, Novartis Pharma.
For Novartis, core principles of corporate social responsibility include being open and accountable regarding clinical trials, preserving the environment through clear, clean techniques, maintaining fair wages and working conditions for employees, and prioritizing research for new cures and treatments.
“Our success lies in our investment in focused research and development and the considerable effort we put in to cultivating local talent. The quality of the people we hire at field level leads to a strong business, which makes a powerful contribution to the lives of people throughout the region,” added Roger Bassoul, General Manager, Novartis Pharma Services Area Manager, Dubai.
Novartis has taken many initiatives, in coordination with Middle East physicians, government authorities and medical centers, to enhance healthcare education and disease awareness in the region.
Novartis has established various initiatives and foundations in many countries around the world. These initiatives range from drug donation and research programs to combat neglected diseases like leprosy, tuberculosis and malaria in developing nations, to patient assistance programs that help cancer patients receive the most innovative and effective treatments available. Last year, over 4.25 million people benefited from Novartis programs valued at USD 570 million.
“Novartis is keen to continue its role in supporting healthy, fulfilled lives for people in the Middle East and beyond,” says MacGillivray.
About Novartis
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2005, the Group's businesses achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Approximately USD 4.8 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 91,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
